Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become the mainstay treatment of metastatic kidney cancer, demonstrating enhanced outcomes and durable responses in select patient subgroups. However, identifying reliable prognostic biomarkers for treatment outcomes remains challenging.

Objectives

This study aimed to assess the correlation between baseline inflammatory markers and overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) in metastatic kidney cancer patients receiving ICIs. CB was defined as patients achieving stable disease, partial response, or complete response.

Design

Retrospective, single-center study.

Methods

A retrospective analysis was conducted on 401 adult patients with advanced kidney cancer treated with ICIs

SUBMITTER: Yildirim A 

PROVIDER: S-EPMC11815817 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature